1. Home
  2. RGC vs LPTX Comparison

RGC vs LPTX Comparison

Compare RGC & LPTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RGC
  • LPTX
  • Stock Information
  • Founded
  • RGC 2014
  • LPTX 2011
  • Country
  • RGC Hong Kong
  • LPTX United States
  • Employees
  • RGC N/A
  • LPTX N/A
  • Industry
  • RGC Medicinal Chemicals and Botanical Products
  • LPTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RGC Health Care
  • LPTX Health Care
  • Exchange
  • RGC Nasdaq
  • LPTX Nasdaq
  • Market Cap
  • RGC 105.3M
  • LPTX 119.6M
  • IPO Year
  • RGC 2021
  • LPTX N/A
  • Fundamental
  • Price
  • RGC $4.50
  • LPTX $0.48
  • Analyst Decision
  • RGC
  • LPTX Buy
  • Analyst Count
  • RGC 0
  • LPTX 3
  • Target Price
  • RGC N/A
  • LPTX $8.50
  • AVG Volume (30 Days)
  • RGC 32.6K
  • LPTX 1.5M
  • Earning Date
  • RGC 10-25-2024
  • LPTX 03-17-2025
  • Dividend Yield
  • RGC N/A
  • LPTX N/A
  • EPS Growth
  • RGC N/A
  • LPTX N/A
  • EPS
  • RGC N/A
  • LPTX N/A
  • Revenue
  • RGC N/A
  • LPTX N/A
  • Revenue This Year
  • RGC N/A
  • LPTX N/A
  • Revenue Next Year
  • RGC N/A
  • LPTX N/A
  • P/E Ratio
  • RGC N/A
  • LPTX N/A
  • Revenue Growth
  • RGC N/A
  • LPTX N/A
  • 52 Week Low
  • RGC $3.03
  • LPTX $0.47
  • 52 Week High
  • RGC $32.44
  • LPTX $4.79
  • Technical
  • Relative Strength Index (RSI)
  • RGC 57.18
  • LPTX 19.00
  • Support Level
  • RGC $3.53
  • LPTX $0.47
  • Resistance Level
  • RGC $3.86
  • LPTX $0.53
  • Average True Range (ATR)
  • RGC 0.21
  • LPTX 0.04
  • MACD
  • RGC 0.10
  • LPTX 0.07
  • Stochastic Oscillator
  • RGC 91.55
  • LPTX 7.42

About RGC Regencell Bioscience Holdings Limited

Regencell Bioscience Holdings Ltd is a bioscience company focusing on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people's immune systems.

About LPTX Leap Therapeutics Inc.

Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .

Share on Social Networks: